eligibility_summary
Adults (>=18) with newly diagnosed locally advanced unresectable or metastatic pancreatic adenocarcinoma (not acinar/neuroendocrine) who, after 2 months of FOLFIRINOX or gemcitabine/nab-paclitaxel, have SD/PR/CR. Must have measurable/evaluable disease, adequate leukapheresis for autologous MT-601, ECOG 0-1, life expectancy >=12 weeks, O2 sat >90% if prior RT, and adequate organ function. Use effective contraception through 6 months post MT-601. Imaging required pre-chemo and pre-MT-601.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06549751 tests MT-601, an autologous, non–genetically engineered cellular therapy comprising patient-derived polyclonal multi–tumor-associated antigen (multiTAA)–specific T cells. Type: biological/cellular immunotherapy. Mechanism: ex vivo–expanded T cells recognize multiple shared TAAs on pancreatic adenocarcinoma via native, MHC-restricted TCRs, then mediate cytotoxic killing (perforin/granzyme) and cytokine-driven immune activation, designed to broaden/avoid single-antigen escape. Target cells/pathways: pancreatic tumor cells expressing TAAs, adaptive T-cell cytotoxic pathways and antigen presentation (MHC I). Given IV during off-weeks of SOC chemo (FOLFIRINOX or gemcitabine/nab-paclitaxel).